Australian Pharmaceutical Industries Limited (API)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: Australian Pharmaceutical Industries Limited
Stock Code: API
GICS Sub-Industry: Health Care Distributors
Market Cap ($M): 805
Equiv. Shares (M): 488

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 1.650 $ 1.630 $ 1.650 $ 1.620 $ 1.630 1,605,396 $ 0.020  1.227 %

Current Broker Consensus Recommendation more
Recommendation: Buy (2)
Recommendation Date: 16th Apr 2015
Brokers Surveyed: 2

Company Overview

Business Description:
Australian Pharmaceutical Industries Limited (API) is an Australian health and beauty services company. API provides wholesale product delivery services, retail services, marketing programs and business advisory services to customers. API also has as a number of brands and banners in the retail health and beauty industry, including Priceline, Soul Pattinson and Pharmacist Advice. API has three main businesses namely, Pharmacy Distribution, Manufacturing and Retail.

Strategy Analysis:
Under the 'Revitalise' plan, a new network plan is forecasted to reduce $18m in annualised cost over 3 years. Total required investment for the program is approximately $60m. Goals include: combining two supply chains into a single system to reduce inventory and freight costs; increase automation at distribution centres; and IT improvements. Revitalise program to consolidate Supply Chain is expected to deliver savings in FY11 of $10m and $18m in FY12. In its retail operations, management is looking to transfer further Priceline corporate stores to franchises. API will also focus is on organic growth in pharmacy and retail operations, as well as improving cost efficiencies.. Australian Pharmaceutical Industries reported NPAT of $30.28m for the year ended 31 August 2012. Revenue from ordinary activities were $3.22bn, down 6.1% from last year. Basic and Diluted EPS were 6.2 cents compared to (4.8) cents last year. Net operating cash flow was $47.82m compared to $48.21m last year. The final dividend declared was 1.5 cents, taking the full year dividend to 3 cents compared with 2.5 cents last year.

Financial Summary
Year to Aug NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016  F -- 9.7 13.4 17.0 5.7 3.4 --
2015  F -- 8.6 -- 19.3 4.1 2.5 --
2014  A -110.9 -22.7 -- 0.0 3.5 6.2 100.0
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Australian Pharmaceutical Industries (API) $796 M -- -- 0.1329 -- 18.9977 16.7695 2.15 2.50 3.48
Primary Health Care (PRY) $2,694 M 0.0787 -0.2071 0.0748 16.3354 20.6032 19.1691 3.80 3.84 4.13
Sonic Healthcare (SHL) $8,341 M 0.1328 0.0261 0.1537 21.7277 21.1756 18.3547 3.23 3.44 3.89
Sigma Pharma. (SIP) $935 M 0.0545 0.2298 0.0488 17.7019 14.3939 13.7239 3.51 5.56 5.84

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
API 0.85 -- 1.68 -- 0.24
Market 0.91 16.4 1.30 2.38 1.62
Sector 0.68 23.0 2.69 2.07 2.89

Name Position Start Date
Mr Stephen Patrick Roche Chief Executive Officer,Managing Director 14 August 2006
Mr Robert Dobson Millner Non-Executive Director 12 May 2000
Ms Esther Carol Holley Non-Executive Director 19 December 2006
Mr Gerard James Masters Non-Executive Director 07 September 2010
Mr Kenneth William Gunderson-Briggs Non-Executive Director 06 May 2014
Ms Lee Ausburn Non-Executive Director 07 October 2008
Mr Peter Raymond Robinson Non-Executive Director,Non-Executive Chairman 05 May 2000

Name Position
Genevieve Ryan Alternate Company Secretary
Graeme Fallet Chief Financial Officer
Peter F Sanguinetti Company Secretary
Stephen Arthurson General Manager, People
Richard Vincent Group General Manager, Business Development & Operations

Substantial Shareholders
Holding Name
32,138,866 (6.58%) Citicorp Nominees Pty Limited
120,214,969 (24.63%) Washington H Soul Pattinson and Co Ltd
58,122,597 (11.91%) S L Nominees Pty Ltd and Associates
31,110,561 (6.37%) J P Morgan Nominees Australia Limited
29,809,565 (6.11%) HSBC Custody Nominees (Australia) Limited

Calendar of Events
Date Event
11 December 2015 Report (Annual)
22 October 2015 Report (Prelim)
29 April 2015 Report (Interim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Choosing A Financial Planner

An educational booklet about the specialised professionals who help people with their money-related requirements - especially superannuation.

More details...


Markets melt up

By Michael McCarthy (chief market strategist, CMC Markets) 19/12/2014 | Traders and investors caught short heading into the FOMC scrambled for cover in Europe and the US, in many cases driving indices to their best one day performance for 2015.

Aussie Investors take their foot off the accelerator

By Betty Lam (Sales Trader, CMC Markets) 18/12/2014 | Lead by the Fed-fervour offshore, Australians shares jumped on the Yellen cheer wagon. The material and energy stocks were back in vogue as both sectors gained over 3% in morning trade.

Fed Feeds Frenzy

By Michael McCarthy (chief market strategist, CMC Markets) 18/12/2014 | In spite of a frenzied pre-mortem, a benign statement from the US Federal Reserve‚Äôs Open Market Committee and steadying commodity markets drove investors back into share markets overnight. A calmer, stronger ruble helped offset European growth fears, highlighted in the overnight session by further declines in inflation.

Household brands Woolworths and Telstra Heavy Lifting

By Betty Lam (Sales Trader, CMC Markets) 11/12/2014 | Offshore jitters sent ripples through to Australian stocks. The open saw the local equities take 65 points off the index, catalysed by a mass-exit in energy stocks, yet again.

Steady open as Woodside investors wait on details of possible Wheatstone acquisition

By Ric Spooner (Chief Market Analyst, CMC Markets) 10/12/2014 | Yesterday‚Äôs news on Greek politics and China‚Äôs bond market came at a time when US and European stock markets have extended rallies and pushed valuations higher. This makes those markets vulnerable to downward corrections as profit takers act to avoid missing out.

MYEFO and Lima - December could be nasty.

BR Securities Australia Pty Ltd 2/12/2014 | December 2014 could go down as a nasty moment in Australian finance. MYEFO will reveal a deteriorating budget deficit and the UNFCCC meeting in Lima, Peru will provide the agreement, to be ratified in Paris in 2015, on how much (or little) CO2 is to be allowed into the atmosphere from 2020.


Sponsored Links